CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
angiotensin converting enzyme inhibitor +1 moredrug
Likely dose
lisinopril 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00874432
NCT00874432Phase 2Completed
CompareCT.gov

Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease

University of Wisconsin, Madison·interventional·Posted Apr 2, 2009·Updated Oct 27, 2020

In Brief

A Phase 2 clinical trial evaluating angiotensin converting enzyme inhibitor and lisinopril for Cardiovascular Disease and Chronic Kidney Disease. Completed, enrolled 43 participants across 1 site.

Detailed Summary

The goal of this proposal is to investigate the potential for ACE-inhibitors (ACE-I)(drugs primarily used to treat hypertension or congestive heart failure) to prevent or delay cardiovascular disease (CVD) in older adults with chronic kidney disease (CKD) by examining their impact on aortic stiffness in people with stage 3 CKD in a randomized, controlled study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease, Chronic Kidney Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2, 2009
Enrollment StartJan 1, 2009
Primary CompletionDec 1, 2009
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.3 years ago

Interventions

angiotensin converting enzyme inhibitordrug

Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day

lisinoprildrug

1 x 40 mg per day